Glz Total Tablet is a combination oral hypoglycemic agent containing Gliclazide 60 mg, Pioglitazone 15 mg, and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. This formulation synergistically improves glycemic control through complementary mechanisms of action. Gliclazide, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Pioglitazone, a thiazolidinedione, enhances peripheral insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), promoting glucose uptake in adipose and muscle tissues. Metformin, a biguanide, primarily decreases hepatic gluconeogenesis and improves insulin sensitivity, contributing to reduced fasting and postprandial glucose concentrations. The combination is particularly beneficial for patients inadequately controlled on monotherapy or dual therapy, offering improved efficacy with a lower risk of hypoglycemia compared to sulfonylurea monotherapy. Glz Total Tablet should be administered as prescribed by a healthcare professional, with dosage adjustments based on glycemic response and tolerance. Caution is advised in patients with renal or hepatic impairment, heart failure, or a history of lactic acidosis. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. This combination therapy supports comprehensive glycemic management in type 2 diabetes, aiming to reduce the risk of long-term complications.